Sales grew by 2.3% to $21.4 billion in Q1 2024, with operating growth of 3.9% and adjusted operating growth of 4.0%.
Excluding the COVID-19 vaccine, Q1 2024 earnings per share (EPS) rose to $2.20 and adjusted EPS increased to $2.71, or 12.4%.
' Johnson & Johnson's strong first-quarter performance reflects our increased focus and progress in our portfolio and pipeline, ' said Joaquin Duato, Group President.
' Our impact across the healthcare spectrum is unique in our industry, and the milestones achieved this quarter reinforce our position as an innovation powerhouse. '
For 2024, J&J says it is now targeting sales growth of 5.5% to 6%, with earnings per share (EPS) expected between $10.60 and $10.75, taking into account the dilutive effect of the Laminar acquisition.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).